Skip to content

First Tracks Biotherapeutics

US · TRAX #3189 by market cap Listed 2026
31.46 +0.87 +2.84%
Live - 5344 symbols - heartbeat 278s ago · 2026-10-08 10:00
Pre-market 32.45 +6.08%
After-hours 29.99 -1.96%
Overnight 31.57 +3.20%
Market cap
1.12B
P/B
6.66
EPS
-4.92
Reader sentiment Are you bullish or bearish on TRAX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • H.C. Wainwright Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $57
    Market Newswire · 2026/9/3
  • Rating change
    UBS Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/8/14
  • Rating change
    Barclays Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/9/3
  • Guggenheim Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $100
    Market Newswire · 2026/9/17
  • Evercore Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $65
    Market Newswire · 2026/9/18
  • Rating change
    Piper Sandler Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $95
    Market Newswire · 2026/8/27
  • Rating change
    Analysts Offer Insights on NA Companies: Arcturus Therapeutics (ARCT), EquipmentShare.com, Inc. (EQPT) and First Tracks Biotherapeutics Inc (TRAX)
    TipRanks · 2026/8/20
  • Rating change
    Piper Sandler Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $54
    Market Newswire · 2026/7/20
  • Rating change
    Analysts Offer Insights on NA Companies: Cerebras Systems, Inc. Class A (CBRS), CitroTech (CITR) and First Tracks Biotherapeutics Inc (TRAX)
    TipRanks · 2026/8/13
  • Rating change
    Wedbush Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $60
    Market Newswire · 2026/7/28
  • Rating change
    UBS Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $65
    Market Newswire · 2026/8/10
  • Rating change
    J.P. Morgan Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $65
    Market Newswire · 2026/8/20
  • Rating change
    A Quick Look at Today's Ratings for First Tracks Biotherapeutics(TRAX.US), With a Forecast Between $57 to $95
    Market Newswire · 2026/8/13
  • Rating change
    Barclays Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $48
    Market Newswire · 2026/7/21
  • Rating change
    Wells Fargo Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/7/28
  • Rating change
    Analysts Offer Insights on NA Companies: First Tracks Biotherapeutics Inc (TRAX), BETA Technologies, Inc. Class A (BETA) and Cerebras Systems, Inc. Class A (CBRS)
    TipRanks · 2026/8/13
  • Rating change
    H.C. Wainwright Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $44
    Market Newswire · 2026/7/28
  • CCORF Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $50
    Market Newswire · 2026/9/30
  • Rating change
    Wells Fargo Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $55
    Market Newswire · 2026/7/28
  • Wedbush Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $70
    Market Newswire · 2026/9/3

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 10:00:16 · For reference only, not investment advice and not tailored to your situation.